Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

NCT01003184 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Exenatide as Monotherapy

NCT00381342 ·Status: COMPLETED ·Phase: PHASE3

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

NCT00111540 ·Status: COMPLETED ·Phase: PHASE3

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

NCT00894322 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes

NCT00516048 ·Status: COMPLETED ·Phase: PHASE3

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

NCT00085969 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

NCT00877890 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

NCT00935532 ·Status: COMPLETED ·Phase: PHASE3

Study of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus

NCT04001231 ·Status: WITHDRAWN ·Phase: PHASE1

Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

NCT02229396 ·Status: COMPLETED ·Phase: PHASE3

A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects

NCT00917267 ·Status: COMPLETED ·Phase: PHASE3

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

NCT00103935 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

NCT00603239 ·Status: COMPLETED ·Phase: PHASE3

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

NCT00641056 ·Status: COMPLETED ·Phase: PHASE3

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

NCT00099619 ·Status: COMPLETED ·Phase: PHASE3

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

NCT00241423 ·Status: COMPLETED ·Phase: PHASE2

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

NCT00099333 ·Status: COMPLETED ·Phase: PHASE2

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817 ·Status: COMPLETED ·Phase: PHASE3

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

NCT02803918 ·Status: COMPLETED ·Phase: PHASE1

Effect on Weight Loss of Exenatide Versus Placebo

NCT00375492 ·Status: COMPLETED ·Phase: PHASE3

Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

NCT02380521 ·Status: COMPLETED ·Phase: PHASE4

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631 ·Status: COMPLETED ·Phase: PHASE3

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

NCT01342484 ·Status: COMPLETED ·Phase: PHASE2

Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

NCT01140893 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

NCT00676338 ·Status: COMPLETED ·Phase: PHASE3